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ABSTRACT
PURPOSE: To analyze the direct costs of conservative surgical treatment of breast cancer, performed in a university hospital, to the 
Brazilian National Health Care Public System (SUS), checking the impact of the oncoplastic approach on these costs. 
METHODS: One hundred thirty eight breast cancer patients who had undergone conservative treatment with oncoplastic approach 
(n=36) or not (control group, n=102), in the period from 2005 to 2010, were enrolled. Sociodemographic and clinical data were recorded. 
The direct costs of the surgical procedure were obtained and analyzed.
RESULTS: Groups did not differ in regard to age (p=0.963), and patients in oncoplastic group had a longer time of hospital stay 
(p=0.000). The median direct cost for the oncoplastic group was R$461.00 and for the control group was R$229.00 (p=0.000). 
CONCLUSION: The oncoplastic approach has generated higher direct costs in conservative surgical treatment of breast cancer to SUS.
Key words: Breast Neoplasms. Mastectomy, Segmental. Surgery, Plastic. Surgical Flaps. Health Care Costs.
RESUMO
OBJETIVO: Analisar os custos diretos do tratamento cirúrgico conservador do câncer mamário, realizado pelo Sistema Único de 
Saúde (SUS) em um hospital universitário, verificando o impacto da abordagem oncoplástica sobre estes custos.
MÉTODOS: Foram incluídas 138 pacientes submetidas ao tratamento conservador do câncer mamário pelo SUS, com abordagem 
oncoplástica (n=36) ou não (grupo controle, n=102), no período de 2005 a 2010. Foram registrados dados sócio-demográficos e da 
operação. Os custos diretos do procedimento cirúrgico foram obtidos e analisados. 
RESULTADOS: Não houve diferença entre os grupos quanto à idade (p=0.963), e o tempo de internação hospitalar foi maior no grupo 
oncoplástica (p=0,000). A mediana dos custos diretos do grupo oncoplástica foi de R$461,00 e do grupo controle foi de R$229,00 
(p=0,000). 
CONCLUSÃO: A abordagem oncoplástica gerou custos diretos maiores para o tratamento cirúrgico conservador do câncer mamário 
pelo SUS. 
Descritores: Neoplasias da Mama. Mastectomia Segmentar. Cirurgia Plástica. Retalhos Cirúrgicos. Custos de Cuidados de Saúde.
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Introduction
Breast cancer is the most common cancer in women, 
and one of the most frequent causes of death by cancer among 
women1. Since its oncological safety has been demonstrated, 
the breast-conserving treatment, which consists of partial breast 
resection associated to radiotherapy, is widely considered the 
standard approach to breast carcinomas of limited diameter2. 
Although breast-conserving treatment is considered to 
be the least disfiguring surgical option for breast cancer patients, 
aesthetic outcomes vary widely, and the majority of women report 
breast asymmetry after breast-conserving treatment. Patients who 
undergo breast-conserving therapy frequently develop breast 
asymmetry from either the surgical removal of tissue or radiation-
related fibrosis, or both3,4.
Various techniques of partial breast reconstruction can 
be used to achieve an aesthetically acceptable result. Immediate 
reconstruction should be undertaken whenever possible, since 
effects of radiation on breast tissue may be a problem when 
reconstruction is delayed5. 
In order to improve the aesthetic results of breast-
conserving treatment, plastic surgery techniques can be performed 
immediately after appropriate oncologic resection; this approach 
is known as oncoplastic surgery6. The oncoplastic surgery is a 
multispecialty collaboration, which includes the mastologist, the 
plastic surgeon, the oncologist and, most importantly, the patient5. 
It is important to identify patients at risk for poor aesthetic results 
after breast-conserving therapy at the time of pre-operative 
consultation because oncoplastic techniques may offer these 
patients improved long-term quality of life4,7. 
Health care is a problem faced by several countries, 
including Brazil. Currently, it has grown the need for studies to 
assess the economic impact of health actions. Breast cancer therapy 
is highly cost-effective, but when financial resources are limited, 
policy-makers must make difficult choices. As governments and 
health care funders confront the issues of ensuring value for money 
within limited health care budgets, relative costs and outcomes are 
important considerations in the development of treatment policy8,9. 
We find none study on cost-effectiveness of immediate 
breast reconstruction following breast-conserving treatment in 
current literature. Thus, this study was designed to analyze the 
direct costs of breast cancer conserving treatment, performed in 
a university affiliated hospital, to the Brazilian National Health 
Care Public System (SUS), assessing the impact of oncoplastic 
approach on these costs.  
Methods
The study protocol was approved by the Institutional 
Ethical Committee, and followed the statements of Helsinki 
Declaration and 196/96 Resolution of the Brazilian National 
Council of Health.
The study was carried out in a university-affiliated 
hospital, during the period from 2005 to 2010. All breast cancer 
patients who had undergone breast-conserving treatment in the 
period, by the Brazilian National Health Care Public System 
(SUS), were considered eligible. One hundred thirty eight patients 
were enrolled; 36 of them underwent oncoplastic surgery and 102, 
which had none breast reconstruction procedure, were allocated in 
control group. Patients who received preoperative chemotherapy, 
with diagnosis of systemic disease or with previous breast surgery 
were excluded from the study. 
Each patient was studied individually, and demographic 
and clinical data were recorded. For the analysis of costs, we 
considered the period of hospitalization of the patient. The direct 
costs of the operation and the postoperative hospital stay, including 
dressings, materials and human costs were assessed by analysis of 
records of hospital costs.
Statistical analysis
Due to the nature of the variables studied, non-parametric 
statistics were used. Mann-Whitney test for independent groups 
was used to compare the groups in regard to age, time of hospital 
stay and costs.  
The rejection level for the null hypothesis was fixed 
at 5% (a£0.05). Statistical analysis was undertaken using SPSS 
version 18 (SPSS, Inc., Chicago, USA).
Results
Table 1 presents the comparison between the two 
groups in regard to the main variables. Patients in both groups 
did not differ in regard to age (p=0.963). Patients who undergone 
oncoplastic surgery had a longer hospital stay (p=0.000). 
The median direct cost for control group was R$229.00, 
and for oncoplastic group, R$461.00 (p=0.000).
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TABLE 1 - Comparison of control and oncoplastic groups in regard to age, time of hospital stay and direct costs.
SD = standard deviation
Discussion
Since long-term results of randomized trials have proven 
the oncological safety of breast-conserving treatment, increasing 
numbers of breast cancer patients have considered this kind 
of treatment2,10. This increase in the use of breast-conserving 
treatment led to a rising interest in long-term aesthetic results and 
patients’ quality of life7. 
Although breast-conserving treatment is considered to 
be the least disfiguring surgical option for breast cancer patients, 
the majority of women report breast asymmetry after this kind 
of treatment3,4. Breast asymmetry may be a constant reminder to 
these patients of their disease and treatment process, impairing 
their psychological adjustment after treatment4. Despite of this, 
breast reconstruction following breast-conserving treatment is not 
routinely offered to patients3. 
Recent healthcare policy has focused increasingly on 
developing appropriate measures of quality for breast cancer 
care4. Reconstructive surgery after mastectomy is likely to be cost-
effective in women who place a value upon it, but this relation has 
not been established for breast-conserving surgery yet11. Despite 
previous studies have demonstrated that breast-conserving 
treatment is more expensive than mastectomy, we find none study 
of costs of breast reconstruction following breast-conserving 
surgery9,12-14.
However, a previous study had shown that the possibility 
of patient choice among breast cancer surgical treatments provided 
a quality of life gain, thus, it was economically attractive when 
the economic analysis included the benefit of patient choice of 
treatment12. We speculate that this principle could be applicable to 
oncoplastic surgery. However, further studies of cost-effectiveness 
of oncoplastic surgery are necessary to test this hypothesis.
The breast plays an important role in female sexuality, 
and the psychosocial impact of mutilation, even partial, result 
of the surgical treatment of breast cancer, is immeasurable. This 
psychosocial impact may result, by itself, in additional costs to 
the public health system. The present study demonstrated that the 








Range 20 - 88 34 – 75
Median 50.5 49.5 p = 0.963
Mean ± SD 50.3 ± 13.2 50.3 ± 8.2
Time of hospital stay 
(days)
Range 1 – 5 2 – 4
Median 2.0 2.5 p = 0.000
Mean ± SD 2.1 ± 0.5 2.6 ± 0.6
Costs (R$)
Range 142.85 – 1024.41 304.94 – 603.46
Median 229.00 461.00 p = 0.000
Mean ± SD 232.40 ± 99.3 453.50 ± 76.9
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National Health Care Public System (SUS). However, the 
effectiveness of the oncoplastic surgery, demonstrated by better 
aesthetic results, patients’ satisfaction and quality of life gains 
should be considered7,15. 
Conclusion
The oncoplastic approach in the breast-conserving 
treatment of breast cancer, performed in a university-affiliated 
hospital, generated higher costs to the Brazilian National Health 
Care Public System (SUS).
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